# Mentoring in Translational Research in Interstitial Lung Diseases

> **NIH NIH K24** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $113,963

## Abstract

Project Summary
The overall goal of this renewal application for a MidCareer Investigator Award in Patient-Oriented Research is
to enable the candidate to continue to expand her research and mentoring programs in sarcoidosis patient-
oriented research. This award will allow her to continue to devote significant protected time to the professional
development of her current mentees with a focus on successful transition to scientific independence. During the
prior award period, the candidate and her mentees identified a crucial role for the Programmed Death-1/STAT3
signaling pathway in Th17 cells to pulmonary sarcoidosis progression. Now this team provides compelling
preliminary data that metformin reduces the percentage of sarcoidosis PD-1+CD4+ T cells in vitro, and that this
reduction is associated with reduced human lung fibroblast (HLF) collagen production. In this renewal
application, Dr. Drake and her mentees will assess the capacity of oral metformin to alter PD-1 expression on
sarcoidosis CD4+ T cells in vivo, as well as identify relevant mechanisms by which this occurs. The team will
determine the impact of oral metformin on sarcoidosis forced vital capacity (FVC), focus on Th17 cell immuno-
metabolomic alterations, as well as alterations in STAT3 signaling. The two specific aims are as follows: 1) To
assess the in vivo efficacy of oral metformin on reduction of PD-1+CD4+ T cells in sarcoidosis subjects and its
impact on sarcoidosis FVC; 2) To assess if oral metformin has the capacity to reduce HLF collagen production
in sarcoidosis subjects. These translational investigations will lay a firm foundation for a future advanced clinical
investigation of metformin efficacy against pulmonary sarcoidosis progression. The results from the proposed
clinical and mechanistic investigations will be translated into advanced clinical trials, thus providing future
mentees with basic, translational and clinical platforms for their career development.

## Key facts

- **NIH application ID:** 10371751
- **Project number:** 2K24HL127301-07A1
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Wonder P. Drake
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $113,963
- **Award type:** 2
- **Project period:** 2016-02-15 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10371751

## Citation

> US National Institutes of Health, RePORTER application 10371751, Mentoring in Translational Research in Interstitial Lung Diseases (2K24HL127301-07A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10371751. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*